Senores Pharmaceuticals Ltd Q2 FY2026 Concall Summary & Transcript Notes

Source transcript PDF: https://www.stockscans.in/document/xjmekxyi68km850bon4fi3ve.pdf

# 1. Financial Performance

## A. Key Figures
   *   **Consolidated Income:** ₹162 Cr Q2 (+61% YoY, +17% QoQ) · ₹300 Cr H1 (+66% YoY)
   *   **EBITDA:** ₹50 Cr Q2 (+113% YoY) · ₹84 Cr H1 (+88% YoY)
   *   **PAT:** ₹30 Cr Q2 (+131% YoY) · ₹51 Cr H1 (+114% YoY)
   *   **Cash Flow from Operations:** ₹31 Cr H1 (vs. ₹9 Cr prior year) · ₹11 Cr in Q2
   *   **EBITDA Margin:** 31% Q2 (+750 bps YoY, +580 bps QoQ)
   *   **H1 EBITDA-to-CFO Ratio:** 38% (Q2: 40%)

## B. Revenue Growth
   *   **Robust Top-Line Momentum:** Revenue growth fueled by successful new product launches in regulated markets, with a broadening, more predictable product mix.
   *   **Sustainable Revenue Streams:** Profit share and licensing fees now form a **major and stable component** of income, reducing reliance on one-off spikes.
   *   **Out-Licensing Contribution:** Out-licensing income in the quarter reached **₹12 Cr**, underscoring IP monetization strength.

## C. Profitability Trends
   *   **Margin Expansion Accelerates:** EBITDA margin surged to 31% in Q2, reflecting operating leverage and disciplined cost management despite rising employee costs.
   *   **Gross Margin Trajectory:** Current gross margin near **55%**, with a clear path to **60–65%** as API integration advances.
   *   **D. S. Segment Profitability:** Consolidated U.S. business (Havix + Senores Inc.) delivers best-in-class **40–42% EBITDA margins**, highlighting value of integrated manufacturing and IP.
   *   **Cost Outlook:** Employee expenses expected to stabilize at **₹27–28 Cr per quarter**, supporting margin predictability.

## D. Balance Sheet
   *   **Working Capital Discipline:** Trade receivables increased but remain within manageable days; working capital cycle expected to hold at **90–100 days**, with H2 pressure from emerging markets.

## E. Cash Flow
   *   **Cash Flow Conversion Strengthens:** H1 operating cash flow tripled YoY, with EBITDA-to-CFO ratio improving to **38% (Q2: 40%)**, signaling enhanced capital efficiency.
   *   **Liquidity & Return Outlook:** Management expects further improvement in cash flow metrics as scale increases, boosting liquidity and return potential.
   *   **OCI Impact:** **₹8 Cr** loss in Other Comprehensive Income due to foreign currency translation adjustments on share transfers.

---

# 2. Product & Segment Performance

## A. Key Figures
   *   **Regulated Markets Revenue:** ₹107 Cr Q2 (+87% YoY, +19% QoQ) · ₹197 Cr H1 (+78% YoY)
   *   **Emerging Markets Revenue:** ₹32 Cr Q2 (+9% QoQ) · ₹61 Cr H1 (+4% YoY)
   *   **Branded Generics Revenue:** ₹12 Cr Q2 (10x YoY) · ₹20 Cr H1 (7x YoY)

## B. Regulated Markets
   *   **Dominant Growth Engine:** Regulated markets, the largest vertical, delivered robust double-digit growth driven by portfolio expansion, proprietary product launches, and strong customer acquisition.
   *   **Margin Expansion:** EBITDA margins improved significantly to **44% in Q2**, reflecting successful in-house ANDA filings and government channel controlled substance launches.
   *   **Own Products Momentum:** Company-owned products in regulated markets grew by **over 60%**, with a profit-share model enhancing profitability and cash flow.
   *   **Revenue Mix Stability:** Regulated segment expected to maintain ~65% of total revenue, with CDMO-CMO contributing ~$12 Mn in visible business and balanced mix between own and contract products.
   *   **Strategic Focus:** Capital allocation and growth initiatives remain centered on regulated markets, underpinned by high pipeline visibility and execution capability.

## C. Emerging Markets
   *   **Operational Recovery:** Emerging markets showed sequential improvement in revenue and profitability, turning cashflow positive despite geopolitical headwinds and dollar volatility.
   *   **Commercialization Delays:** Despite 80+ product registrations, growth constrained by import permit bottlenecks and delayed order conversion, limiting YoY momentum.
   *   **Margin Upside Ahead:** Margins expected to reach **early double-digits by year-end**, supported by niche molecule focus and improved pricing, boosting blended EBITDA.
   *   **Diversification Playbook:** Strategic push into emerging markets with 1,000+ registrations aims to de-risk geographic concentration and leverage long-term growth in high-potential regions.

## D. Branded Generics
   *   **Explosive Growth Trajectory:** India’s branded generics business achieved over 7-fold H1 revenue growth, with PAN-India rollout and hospital channel penetration accelerating scale.
   *   **Scalable Margin Profile:** EBITDA margins at **18–20%** with expansion expected as reach and portfolio grow; business generates positive cash flow from inception.
   *   **Pipeline & Capacity:** CDMO-CMO portfolio expanded to ~32 products with **50+ in pipeline**, supported by U.S.-based manufacturing for supply chain agility.
   *   **Strategic Partnerships:** Zoraya’s U.S. marketing infrastructure and Senores Inc.’s IP holdings derisk and accelerate CGT and generic product launches.
   *   **Revenue Outlook:** Branded generics on track for ~₹50 Cr in FY26, with target to double to **₹100 Cr+ next year** through new divisions and expanded footprint.

---

# 3. Product Portfolio & Launches

## A. Key Figures
   *   **New Product Launches:** **8** in Q2 FY'26
   *   **Regulated Market Portfolio:** **81** products
   *   **Products Under Registration:** **824** in emerging markets
   *   **Registered Products:** **394** as of Sep-30, 2025

## B. New Product Launches
   *   **Accelerated Innovation:** Robust new product cadence with **8 launches in Q2**, including from the acquired ANDA portfolio, enhancing basket diversification and growth runway.
   *   **Zoraya Platform Rollout:** Strategic branded platform launched to commercialize key acquired products under company label, signaling enhanced control over positioning and pricing.
   *   **Sustained Launch Momentum:** Management targets **quarterly product launches over the next 4–5 quarters**, focused on regulated markets, with potential tailwinds for margin performance.
   *   **Semaglutide Progress:** Tablet dossier filed in **12–14 ROW markets**; injectable version under filing in multiple emerging markets, unlocking a **significant growth opportunity** despite lack of third-party market data.

## C. ANDA Pipeline
   *   **Deep Regulated Pipeline:** **Close to 70 products in development**, with **8–10 ANDAs planned for H1 FY'27** and **6–8 in second half of current year**, reinforcing visibility into future launches.

## D. Registration Progress
   *   **Strong Regulatory Throughput:** **86 new product approvals in the quarter** reflect improved agency engagement and pipeline velocity in emerging markets.

---

# 4. Manufacturing & Capacity

## A. Key Figures
   * U.S. Capacity: 2 billion units post-expansion (+67% from 1.2B)

   **B. S. Capacity:** **200 Cr units** post-expansion (+67% from 120 Cr)
   *   **Ratnatris Revenue:** **₹55–56 Cr** at acquisition · **₹150 Cr** projected by FY'25 (+~3x)
   *   **Product Registrations (Ratnatris):** **47–48** at acquisition · **394** by FY'25 (+6x)
   *   **Per-Unit Realization (Ratnatris):** **₹2** pre-CFY · **₹8–9** currently (+300%)
   *   **New API Facility Revenue (Year 1):** **₹50–100 Cr** targeted

## B. U.S. Facility Expansion
   *   **Strategic Capacity Buildout:** U.S. manufacturing footprint set to double with two new lines—third line in Q3 FY'26, fourth by end-FY'26—providing ample headroom for growth.
   *   **Sterile Capability On Horizon:** First sterile facility in the U.S. targeting launch in Q2/Q3 FY'27, enabling entry into **general injectables and biologic CDMO-CMO** markets.
   *   **Greenfield Execution Track Record:** Havix, a fully built-from-scratch facility, achieved commercial launch in 2019 post-inspection, demonstrating proven execution capability.
   *   **Integration Challenges Persist:** Ratnatris and Havix synergies remain delayed, with concerns over **continued siloing of U.S. manufacturing and India R&D teams** as separate cost centers.

## C. API Integration
   *   **Backward Integration Accelerating:** First API facility targeting US FDA approval in Q2 FY'26–FY'27; second facility to commence production post-approval, enhancing supply chain control.
   *   **Margin Expansion Pathway:** Management guides to a **sustainable gross margin of 60–65%**, supported by in-house API integration, though full impact not quantifiable before FY'27–FY'28.

---

# 5. Supply Chain & Vertical Integration

## A. API Sourcing Strategy
   *   **Cost-Driven Make-or-Buy Approach:** API sourcing decisions will prioritize economic efficiency, with external procurement retained where it outperforms captive production.
   *   **Strategic Self-Sufficiency Push:** Plans to bring **certain API production in-house within 1–2 years** to secure supply chain continuity for critical formulations.

## B. Backward Integration
   *   **Macro-Integration Underway:** A comprehensive backward integration strategy is being executed, anchored by an **API facility with over 100 metric tons annual capacity**.
   *   **Regulated Markets in Focus:** API investments are largely complete, with ongoing prioritization in regulated markets and only incremental spend for mid-tier standardized markets.

---

# 6. Risks & Regulatory Exposure

## A. Geopolitical & Execution Risks
   *   **Past Disruptions Contained:** Havix operations faced significant setbacks during 2020–2021 due to pandemic-related lockdowns, delaying integration and performance expectations.
   *   **Limited Competitive Replication:** Despite apparent viability, few peers have successfully replicated the model—potential execution slippage or mid-cycle dropouts may be inhibiting adoption.
   *   **No Materialized Threats:** Key strategic risks remain unmanifested; leadership emphasizes that current opportunities are below thresholds where exclusivity expiry would trigger immediate, large-scale competition.

## B. Supply Chain Resilience
   *   **Low China Exposure:** Only **one API** is currently sourced from China, significantly reducing vulnerability to tariffs and regional supply shocks.
   *   **De-risking Regulated Supply Chains:** In markets like the US, certain products depend on single-source API suppliers, but internal API capacity is under development to reduce long-term dependency.

---

# 7. Guidance & Outlook

## A. Key Figures
   *   **Revenue Growth Guidance:** **25%–30%** sustainable CAGR post-FY'26 (ex-cl. sterile facilities)
   *   **Gross Margin Guidance:** **60%–65%**
   *   **EBITDA Margin Outlook:** **28%–30%** sustainable from next year; **40%–45%** for combined US entity
   *   **Regulated Markets Contribution:** **>40%** of total business
   *   **Regulated Markets Margins:** **40%–42%** (expected stabilization)

## B. Revenue Targets
   *   **Double-Digit Momentum:** Emerging markets on track for double-digit growth in FY'26–FY'27, with current-year growth reaffirmed.
   *   **Long-Term Scaling Ambition:** Management targets **at least 30% CAGR over 3–5 years**, driven by product launches, though characterized as internal aspiration.
   *   **CDMO-CMO Strength:** Business has seen multi-fold year-on-year expansion, with trajectory supporting **>30% CAGR** in coming years.
   *   **Sterile Facility Exclusion:** Current growth guidance does not factor in future contributions from sterile operations, which remain in early planning.

## C. Margin Expectations
   *   **Profitability Framework:** Company expects to sustain **overall profitability margins of 40%–42%**, supported by high-margin regulated segments.
   *   **EBITDA Resilience:** Margins expected to remain stable from next year onward, with **like-to-like PAT margin expansion of a few hundred bps** anticipated due to low leverage.
   *   **US Entity Premium:** Combined US operations projected to maintain **40%–45% EBITDA margins**, significantly above legacy Ratnatris levels.
   *   **Seasonal Trend Continuity:** H2 typically outperforms H1; no lumpiness expected, supporting margin consistency.